Oct 17, 2022
From 11:30 AM to 12:30 PM

Location 110, avenue des PinsMontréal, QC, H2W 1R7Canada
ContactChristine Matte, Coordonnatrice aux affaires académiques / Academic Affairs Coordinator
IRCM Conference

Sekar Kathiresan, MD

Sekar Kathiresan, MD

From reading the genome for risk to rewriting it for cardiovascular health

Sekar Kathiresan, MD
Co-Founder and Chief Executive Officer
Verve Therapeutics
Cambridge, MA, USA

The host of this conference is Nabil G. Seidah, PhD. This conference is part of the 2022-2023 IRCM conference calendar.

In person: 
IRCM Auditorium
110, avenue des Pins O, H2W 1R7 Montreal
Wearing a mask is mandatory at all times

Zoom Link : https://zoom.us/j/95269762104
ID : 952 6976 2104
Code : 476372

IRCM conferences are set to occur under a hybrid format. However, please note that last-minute changes to online-only lectures may occur due to unforeseen circumstances. We invite you to visit this webpage again a few days before attending.


About this conference: 
Presentation objectives:
1. To understand the two major genetic models for myocardial infarction risk – monogenic and polygenic
2. To describe how natural resistance mutations lower plasma apoB-containing lipoproteins lifelong in some people and lead to protection against atherosclerotic cardiovascular disease
3. To understand the development of a new class of medicines, which can edit the genome in an adult and potentially lead to permanent lowering of LDL cholesterol after a single dose

Atherosclerotic cardiovascular disease (ASCVD) is a heritable, common, complex disease and the leading cause of death in the world. In this lecture, I will review progress in our understanding of the inherited basis for risk as well resistance to ASCVD. I will then turn to approaches to “rewrite” the genome using gene editing to treat ASCVD.

Musunuru, K., Chadwick, A.C., Mizoguchi, T. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021 May;593(7859):429-434.

About Sekar Kathiresan:
Dr. Sekar Kathiresan is the Co-founder and CEO of Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Dr. Kathiresan is a cardiologist and scientist who has focused his career on understanding the inherited basis for heart attack and leveraging those insights to improve the care of cardiovascular disease. For his research contributions, he has been recognized by the American Heart Association with its highest scientific honor - a Distinguished Scientist Award and by the American Society of Human Genetics with the 2018 Curt Stern Award.

To make sure you don't miss any of the IRCM conferences, sign up now for our newsletter!


events and more


IRCM Foundation

Be part of the

Support health research